This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05861/identifier/chemspider/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05861/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05861/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05861
rdf:type
n4:Drug
n4:description
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
n4:generalReferences
# Dalrymple SL, Becker RE, Isaacs JT: The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate. 2007 May 15;67(7):790-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17373719 # Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Bjork A, Olsson A, Leanderson T: Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006 Dec 1;66(16):1768-78. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16955399
n4:group
investigational
n4:indication
Investigated for use/treatment in prostate cancer.
owl:sameAs
n11:DB05861
dcterms:title
TASQ
adms:identifier
n7:DB05861 n8:15561101 n9:10437676
n4:synonym
tasquinimod
n4:IUPAC-Name
n5:271B47E2-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B47E8-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B47E7-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B47E4-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B47E5-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B47E6-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B47E0-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B47E1-363D-11E5-9242-09173F13E4C5 n5:271B47DE-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B47DF-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Acceptor-Count
n5:271B47EE-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B47EF-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B47E9-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B47EA-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B47EC-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B47EB-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B47ED-363D-11E5-9242-09173F13E4C5
n4:Bioavailability
n5:271B47F4-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B47F6-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B47F7-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B47F3-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B47F2-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B47F5-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B47E3-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B47F0-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B47F1-363D-11E5-9242-09173F13E4C5